Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Entrada Therapeutics, Inc. (TRDA) had Consolidated Net Income/Loss of $-17.35M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$20.56M |
|
$-17.35M |
|
-- |
|
$20.56M |
|
$42.35M |
|
$-21.79M |
|
$4.44M |
|
$-17.35M |
|
$-17.35M |
|
$-17.35M |
|
$-17.35M |
|
|
Consolidated Net Income/Loss |
$-17.35M |
$-17.35M |
|
$-21.79M |
|
$-22.18M |
|
41.07M |
|
41.07M |
|
$-0.42 |
|
$-0.42 |
|
| Balance Sheet Financials | |
$403.19M |
|
$10.67M |
|
$83.29M |
|
$486.48M |
|
$18.43M |
|
-- |
|
$50.79M |
|
$69.22M |
|
$417.26M |
|
$417.26M |
|
$417.26M |
|
37.94M |
|
| Cash Flow Statement Financials | |
$-38.51M |
|
$4.78M |
|
$0.35M |
|
$105.16M |
|
$71.79M |
|
$-33.37M |
|
$5.09M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.88 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-105.99% |
|
-105.99% |
|
-- |
|
-84.39% |
|
-84.39% |
|
$-39.65M |
|
-- |
|
-- |
|
-- |
|
0.04 |
|
-- |
|
10.06 |
|
8.95 |
|
-4.16% |
|
-4.16% |
|
-3.57% |
|
-4.16% |
|
$11.00 |
|
$-0.97 |
|
$-0.94 |
|